GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » Long-Term Debt & Capital Lease Obligation

KNSA (Kiniksa Pharmaceuticals International) Long-Term Debt & Capital Lease Obligation : $7.6 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals International Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Kiniksa Pharmaceuticals International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $7.6 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Kiniksa Pharmaceuticals International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $7.6 Mil. Kiniksa Pharmaceuticals International's Total Assets for the quarter that ended in Mar. 2025 was $599.3 Mil. Kiniksa Pharmaceuticals International's LT-Debt-to-Total-Asset for the quarter that ended in Mar. 2025 was 0.01.

Kiniksa Pharmaceuticals International's LT-Debt-to-Total-Asset declined from Mar. 2024 (0.02) to Mar. 2025 (0.01). It may suggest that Kiniksa Pharmaceuticals International is progressively becoming less dependent on debt to grow their business.


Kiniksa Pharmaceuticals International Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Kiniksa Pharmaceuticals International's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiniksa Pharmaceuticals International Long-Term Debt & Capital Lease Obligation Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only 4.88 2.67 2.62 10.01 7.86

Kiniksa Pharmaceuticals International Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.86 9.32 8.56 7.86 7.62

Kiniksa Pharmaceuticals International Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Kiniksa Pharmaceuticals International  (NAS:KNSA) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Kiniksa Pharmaceuticals International's LT-Debt-to-Total-Asset ratio for the quarter that ended in Mar. 2025 is calculated as:

LT-Debt-to-Total-Asset (Q: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2025 )/Total Assets (Q: Mar. 2025 )
=7.623/599.326
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Kiniksa Pharmaceuticals International Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals International's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiniksa Pharmaceuticals International Business Description

Traded in Other Exchanges
N/A
Address
23 Old Bond Street, Floor 3, London, GBR, W1S 4PZ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Executives
Sanj K Patel director, 10 percent owner, officer: Chairman & CEO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eben Tessari officer: Chief Business Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
John Paolini officer: Chief Medical Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael R Megna officer: Chief Accounting Officer 1050 HINGHAM STREET, ROCKLAND MA 02370
Ross Moat officer: Group VP & Rilonacept GM C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Mark Ragosa officer: Interim CFO C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421
Barry D Quart director C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Arian Pano officer: Chief Clinical Dev. Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham 10 percent owner, officer: Chief Legal Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
G Bradley Cole director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063